| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Articles |
Department of Ophthalmology, Huddinge Hospital, Stockholm, Sweden.
The roles of thyroid hormones and thyrotropin (TSH) in the development of Graves' ophthalmopathy are not clear. Some studies suggest a protective effect of thyroid hormones on experimental exophthalmos and an adverse effect of increased TSH levels. In September 1988 we introduced early thyroxine (T4) administration after 131I therapy for hyperthyroidism caused by Graves' disease. We carried out a retrospective study of records from all patients with this disease treated with 131I for 4 years. During the first 2 years 248 patients were treated (group A). They received T4 when the serum concentration of TSH and/or T4 indicated hypothyroidism. During the next 2 years 244 patients were treated (group B). They were all given 0.05 mg of T4 daily, starting 2 weeks after therapy, and 0.1 mg after a further 2 weeks. With a follow-up of 18 months, 45 patients (18%) in group A and 27 patients (11%) in group B developed or deteriorated in an already present ophthalmopathy (p = 0.03, relative risk = 1.64, 95% confidence interval = 1.05-2.55). Twenty-six patients in group A required specific therapy for the ophthalmopathy (e.g. antithyroid drugs, steroids, etc.) compared to 11 patients in group B (p = 0.02, relative risk = 2.33; 95% confidence interval = 1.18-4.60). Our results suggest that early administration of T4 after 131I therapy reduces the occurrence of Graves' ophthalmopathy.
This article has been cited by other articles:
|
|
 |
|
  J. C. Sisson, M. J. Schipper, C. C. Nelson, J. E. Freitas, and B. R. Frueh Radioiodine Therapy and Graves' Ophthalmopathy J. Nucl. Med., June 1, 2008; 49(6): 923 - 930. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Bartalena, L. Baldeschi, A. Dickinson, A. Eckstein, P. Kendall-Taylor, C. Marcocci, M. Mourits, P. Perros, K. Boboridis, A. Boschi, et al. Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO Eur. J. Endocrinol., March 1, 2008; 158(3): 273 - 285. [Full Text] [PDF]
|
|
|
|
|
|
S. Razvi, B. Vaidya, P. Perros, and S. H S Pearce What is the evidence behind the evidence-base? The premature death of block-replace antithyroid drug regimens for Graves' disease. Eur. J. Endocrinol., June 1, 2006; 154(6): 783 - 786. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Perros, P. Kendall-Taylor, C. Neoh, S. Frewin, and J. Dickinson A Prospective Study of the Effects of Radioiodine Therapy for Hyperthyroidism in Patients with Minimally Active Graves' Ophthalmopathy J. Clin. Endocrinol. Metab., September 1, 2005; 90(9): 5321 - 5323. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J M Kim, L LaBree, L Levin, and S E Feldon The relation of Graves' ophthalmopathy to circulating thyroid hormone status Br. J. Ophthalmol., January 1, 2004; 88(1): 72 - 74. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Ginsberg Diagnosis and management of Graves' disease Can. Med. Assoc. J., March 4, 2003; 168(5): 575 - 585. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Bartalena, A. Pinchera, and C. Marcocci Management of Graves' Ophthalmopathy: Reality and Perspectives Endocr. Rev., April 1, 2000; 21(2): 168 - 199. [Abstract] [Full Text]
|
|
|
|
 |
|
 L. Bartalena, C. Marcocci, F. Bogazzi, L. Manetti, M. L. Tanda, E. Dell'Unto, G. Bruno-Bossio, M. Nardi, M. P. Bartolomei, A. Lepri, et al. Relation between Therapy for Hyperthyroidism and the Course of Graves' Ophthalmopathy N. Engl. J. Med., January 8, 1998; 338(2): 73 - 78. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. M. Wiersinga Preventing Graves' Ophthalmopathy N. Engl. J. Med., January 8, 1998; 338(2): 121 - 122. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
